Updates are available Correction dated 2023-12-01
Click to view Correction: https://doi.org/10.1007/s12325-023-02723-7
Updates are available Correction dated 2024-10-25
Click to view Correction: https://doi.org/10.1007/s12325-024-03011-8
-
Authors
Nagase, Hiroyuki https://orcid.org/0000-0002-0296-5901
Ito, Risako
Ishii, Moe
Shibata, Hideki
Suo, Shintaro
Mukai, Isao
Zhang, Shiyuan https://orcid.org/0000-0001-8523-0419
Rothnie, Kieran J.
Trennery, Claire
Yuanita, Liza
Ishii, Takeo https://orcid.org/0000-0001-6865-1967
-
Funding
Funding for this research was provided by:
GSK (GSK Study 214955)
- License Information
-
More Information
Article History
Received: 19 May 2023
Accepted: 21 August 2023
First Online: 12 September 2023
Change Date: 1 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-023-02723-7
Change Date: 25 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-024-03011-8
Declarations
:
: Hiroyuki Nagase has received speaker and consultation fees from GSK, and speaker fees from AstraZeneca, Boehringer Ingelheim, Kyorin Pharmaceutical, Novartis and Sanofi. Risako Ito, Shiyuan Zhang, Kieran J. Rothnie and Liza Yuanita are employees of GSK and own stocks/shares in GSK. Isao Mukai is an employee of GSK. Claire Trennery and Takeo Ishii were employees of GSK at the time of the study and own stocks/shares in GSK. Hideki Shibata and Shintaro Suo are employees of Mebix, Inc., an agency that received funding from GSK to undertake this study; Moe Ishii was an employee of Mebix, Inc. at the time of the study.
: This study was carried out in accordance with the Declaration of Helsinki, Ethical Guidelines for Medical and Biological Research Involving Human Subjects, and Japanese laws and regulations. Prior to study initiation, documented approval was obtained from the Takahashi Clinic Ethics Committee (LNW00148). To enrol in the study, participants first provided electronic informed consent. Individuals had the option to discontinue their participation at any point, whereupon they were considered as not consenting and were discounted as survey responders. Data collected were anonymised and all data were processed in compliance with the Act on the Protection of Personal Information and related notices applicable to the protection of personal information.
